Characterization of ENU-induced Mutations in Red Blood Cell Structural Proteins

Katrina Kildey ab, Robert L. Flower ab, Thu V. Tran c, Robert Tunningley c, Jonathan Harris b, Melinda M. Dean a*

Abstract: Murine models with modified gene function as a result of N-ethyl-N-nitrosourea (ENU) mutagenesis have been used to study phenotypes resulting from genetic change. This study investigated genetic factors associated with red blood cell (RBC) physiology and structural integrity that may impact on blood component storage and transfusion outcome. Forward and reverse genetic approaches were employed with pedigrees of ENU-treated mice using a homozygous recessive breeding strategy. In a “forward genetic” approach, pedigree selection was based upon identification of an altered phenotype followed by exome sequencing to identify a causative mutation. In a second strategy, a “reverse genetic” approach based on selection of pedigrees with mutations in genes of interest was utilised and, following breeding to homozygosity, phenotype assessed. Thirty-three pedigrees were screened by the forward genetic approach. One pedigree demonstrated reticulocytosis, microcytic anaemia and thrombocytosis. Exome sequencing revealed a novel single nucleotide variation (SNV) in Ank1 encoding the RBC structural protein ankyn-1 and the pedigree was designated Ank1 Exs4. The reticulocytosis and microcytic anaemia observed in the Ank1 Exs4 pedigree were similar to clinical features of hereditary spherocytosis in humans. For the reverse genetic approach three pedigrees with different point mutations in Spnb1 encoding RBC protein spectrin-1β, and one pedigree with a mutation in Epb4.1, encoding band 4.1 were selected for study. When bred to homozygosity two of the spectrin-1β pedigrees (a, b) demonstrated increased RBC count, haemoglobin (Hb) and haematocrit (HCT). The third Spnb1 mutation (spectrin-1β c) and mutation in Epb4.1 (band 4.1) did not significantly affect the haematological phenotype, despite these two mutations having a PolyPhen score predicting the mutation may be damaging. Exome sequencing allows rapid identification of causative mutations and development of databases of mutations predicted to be disruptive. These tools require further refinement but provide new approaches to the study of genetically defined changes that may impact on blood component storage and transfusion outcome.

Introduction

Red blood cell transfusion remains an essential medical therapy for the treatment of a broad range of anaemias. Currently packed red blood cells (PRBCs) for clinical transfusion have a 42 day expiry post-collection. During storage red blood cells (RBC) undergo numerous biophysical and biochemical changes [1,2] (termed the storage lesion) that may alter the biological function of the transfused RBC and/or the immune response of patients post-transfusion. Clinical studies have reported an association between RBC storage and onset of the storage lesion [3-5]. In addition, there is evidence of donor variability in the lifespan of RBCs in storage and onset of the storage lesion [6].

There are two alternative approaches for investigation of association of the product of a genetic open reading frame to a phenotype, referred to as reverse and forward genetics. The “reverse genetic” approach investigates the function of a known gene by phenotypic analysis of cells or organisms in which the function of this gene is impaired [7]. In contrast, the “forward genetic” approach is a tool to identify modifications in cells or organisms through phenotypic analysis, then determine the genetic basis of an altered phenotype [8]. In this study, we have investigated both the forward and reverse approaches to study single nucleotide variation (SNV)-based changes in proteins critical for RBC function that may impact on blood component storage and transfusion outcomes using the N-ethyl-N-nitrosourea (ENU)-mutagenised murine model.

ENU mutagenesis is a technique utilised to produce new pedigrees of mice with SNVs that facilitate investigation of protein function and disease states. ENU is a DNA-alkylating agent that introduces a high rate of random genome-wide SNVs into the mouse germline by affecting the spermatogonial (premeiotic) germ cells in the mice testes [9]. Importantly, the phenotypes from these point mutations more closely model human genetic variation than mouse transgenic models, as 70% of the disease causing alleles so far described in humans are the result of SNVs [10]. SNVs are more likely to result in inactive or altered function of a particular domain of a protein, highlighting active sites or functions of variant forms of the protein. ENU-mutagenised mice are available for selection from a number of libraries for investigation of a defined gene mutation (reverse genetics). In addition new gene function and potential disease association can be discovered by screening ENU pedigrees for phenotypes of interest (forward genetics).
Table 1. Pedigrees selected for mutations in RBC structural genes.

| Gene (Protein) | Chromosome | Base change | Amino acid change | Amino acid position | Mutation genomic position (bp) | Domain | PolyPhen score |
|----------------|------------|-------------|------------------|---------------------|--------------------------------|--------|----------------|
| Spnb1(Spectrin-1β) (a) | 12 | A→G | S→P | 857 | 76,620,753 | Spectrin-binding | 0.24 benign |
| Spnb1(Spectrin-1β) (b) | 12 | T→C | D→G | 664 | 76,621,331 | Spectrin-binding | 0.2 benign |
| Spnb1(Spectrin-1β) (c) | 12 | T→C | K→E | 462 | 76,623,169 | Spectrin-binding | 1 possibly damaging |
| Epbt1(Band 4.1) | 10 | A→G | T→A | 669 | 25,501,836 | hydrophilic | 0.77 possibly damaging |

Table 2. Forward and reverse primers utilised for genotyping ENU-induced mutations in mice.

| Gene | Genotype | Forward primer | Reverse Primer |
|------|----------|----------------|----------------|
| Spnb1 (a) | Variant | GAAGGTCGGGTAACGGATTTAAGCCCTTCCCGGGAGC | TCTGCCAGGCTCAGGGCAT |
| | Reference | GAAGGTGACCAAGGTACCTGCTACACGGTACATTG | |
| Spnb1 (b) | Variant | GAAGGTCGGGTAACGGATTTAAGCCCTTCCCGGGAGC | TCTGCCAGGCTCAGGGCAT |
| | Reference | GAAGGTGACCAAGGTACCTGCTACACGGTACATTG | |
| Spnb1 (c) | Variant | GAAGGTCGGGTAACGGATTTAAGCCCTTCCCGGGAGC | TCTGCCAGGCTCAGGGCAT |
| | Reference | GAAGGTGACCAAGGTACCTGCTACACGGTACATTG | |
| Epbt1 | Variant | GAAGGTCGGGTAACGGATTTAAGCCCTTCCCGGGAGC | TCTGCCAGGCTCAGGGCAT |
| | Reference | GAAGGTGACCAAGGTACCTGCTACACGGTACATTG | |
| Ank1 | Variant | GAAGGTCGGGTAACGGATTTAAGCCCTTCCCGGGAGC | TCTGCCAGGCTCAGGGCAT |
| | Reference | GAAGGTGACCAAGGTACCTGCTACACGGTACATTG | |

Mature human RBC’s have a biconcave discoid shape and can survive shearing stress and undergo elastic deformation to allow passage through capillaries. The elastic filamentous RBC cytoskeleton is composed of four major interconnected components: spectrin-1α (240 kDa), spectrin-1β (220 kDa), band 4.1 (80 kDa) and actin (200 kDa). Disruptions to these protein interactions have been associated with genetically-inherited RBC-related diseases in human populations including hereditary spherocytosis (HS), elliptocytosis, stomatocytosis and pyropoikilocytosis [15-17]. In addition to effects on RBC morphology and structural integrity, disruptions in RBC cytoskeletal proteins have been reported to impact on RBC survival and/or differentiation [18,19]. Human and murine RBCs share a similar cytoskeletal structure [20], though they differ somewhat in lifespan (human RBC predicted 120 days, murine RBC estimated 50 days) in circulation [21]. Murine RBC have been used to model human RBC-related disease [22-24] and provide a suitable platform to study genetic changes in RBCs that may impact on the structural integrity, differentiation and survival of RBCs and therefore component storage and transfusion outcomes.

In this study, we have used murine ENU-mutated models, using both the forward and reverse genetic approaches, to investigate the effect of SNV-based changes on RBC. Pedigrees with SNVs in Epbt1 (encoding band 4.1), and three different SNVs in Spnb1 (encoding spectrin-1β), selected for the reverse genetic approach, demonstrated some perturbation of haematological parameters. In contrast, the forward genetic approach resulted in the generation of a pedigree characterised by reticulocytosis, microcytic anaemia and thrombocytosis. This phenotype was determined to be the result of a novel mutation in Ank1, encoding the RBC structural protein ankyrin-1.

Experimental procedures

ENU-Mutagenesis

ENU-mutagenesis was performed on C57BL/6 mice by the Australian Phenomics Facility (Australian National University (ANU) Canberra) [9,25]. Briefly, male C57BL/6 mice were treated with three intraperitoneal injections of 80 μg ENU/gram of body weight. Ten weeks post mutagenesis ENU-treated males were crossed with multiple female C57BL/6 mice to produce pedigrees with randomly incorporated point mutations. ENU-pedigrees on a C57BL/6 genetic background were produced using a three generation approach to reveal recessive mutations [9]. To reduce the mutation load in the resultant pedigrees G1 mice were crossed with background C57BL/6 mice, and G2 siblings mated (or G2 backcrossed to G1) to generate homozygous G3 mice. Mice were maintained at the Australian Phenomics Facility, Canberra. Animal protocols were reviewed and approved by the Australian National University experimentation ethics committee, and all procedures were carried out under the guidelines of the Australian code of practice for the care and use of animals for scientific purposes.
Pedigree screening for altered haematological phenotype (forward approach)

Using a forward genetics approach an ENU-induced mutant pedigree was selected for further breeding and analysis based on an identifiable phenotype. Briefly, using a “homozygote recessive” breeding strategy, blood from 33 ENU-induced mutant pedigrees was screened for evidence of a changed blood picture by a differential cell count (RBC, platelet, white blood cell (WBC), neutrophil, lymphocyte, monocyte, eosinophil, basophil, and reticulocytes) and measurement of standard haematological parameters (Hb, HCT, and mean corpuscular volume (MCV)) undertaken using an ADVIA analyser (Siemens Healthcare Global). Mice with altered haematological parameters were selectively bred. Causative mutations were identified via exome sequencing (G4 mice). Where indicated mice were sacrificed, spleens excised and measured (wet weight (g), length (cm)).

Selection of ENU-pedigrees from missense mutation library (reverse approach)

Based on the presence of ENU-induced mutation in RBC structural proteins, four pedigrees were selected from the Australian Phenomics Facility missense mutation library [26]. Three pedigrees, each with different SNV in Spob1 (encoding spectrin-β1), and one pedigree with a SNV in Epb4.1 (encoding band 4.1) were selected for assessment in a “reverse genetics” approach to investigate factors that may alter RBC integrity (Table 1). Homozygous pedigrees for the Epb4.1 SNV and the three individual Spob1 SNVs were generated from G2 heterozygous mice using genetic screening. All genomic positions of the mutations were referenced to the Genome Reference Consortium Mouse Build 38 (GRCm38).

Exome sequencing

ENU variations were identified via exome sequencing as previously described [25]. Briefly, exome enriched, paired end libraries were prepared from genomic DNA of each sample. The Illumina paired-end genomic DNA sample preparation kit (PE-102-1001, Illumina) was used for preparing the libraries including end repair, A-tailing and ligation of the Illumina adaptors. Nimblegen SeqCap baits (#999042611, Roche Diagnostics) designed to 203,225 exons and 54Mb of the reference coding regions were used to enrich for the mouse exome. Each sample was prepared with an index using the Illumina multiplexing sample preparation oligonucleotide kit (PE-400-1001, Illumina) and then pooled in batches of four in equimolar amounts prior to capture. Each capture was sequenced in a single lane of a HiSeq 2000 (Illumina) as 100bp paired end libraries. Sequence reads were mapped to the mouse reference assembly and SNVs identified and annotated [23].

SNV genotyping

Primers were designed using Amplifluor™ Assay Architect™ online design program (Table 2). Multiplexed PCR was performed in 96 well plates on Eppendorf MasterCycler ProS thermocycler (POCD Pty Ltd, Artarmon, NSW). Genomic DNA (gDNA) was obtained from 2-3 mm ear punch. Sample was prepared by adding the ear tissue to 15 µl of TE-Tween Lysis buffer (50 mM Tris HCl, pH 8.0, 0.125 mM EDTA, 2% Tween 20) and sample centrifuged (2 min, 2500 g). The prepared tissue sample was digested in 15 µl ear punch digestion mix (14 µl TE-Tween Lysis Buffer, 1.0 µl Proteinase K (20 mg/ml)), by incubating at 55°C for 1 hour, followed by 99°C for 10 min to denature the proteinase K. Samples were centrifuged (10 min, 2500 g) and washed with 180 µl of sterile ddH2O.

PCR was performed in a 5 µl reaction containing 1 µl of gDNA, 0.1 µM PCR Amplifluor primer mix, 0.25 µM amplifluor universal FAM Primer (IDT), 0.25 µM amplifluor universal JOE Primer (IDT), 0.2 mM dNTPs each, 10x Taq DNA Polymerase PCR buffer (Invitrogen), 1.8 mM MgCl2, and 0.05 units of MyTaq™ HS DNA Polymerase. PCR cycling conditions were 95°C for 4 min, followed by 35 cycles of 95°C for 10s, 60°C for 20s and 72°C for 10s followed by a final elongation of 72°C for 3 min.

Bioinformatics modelling

To further annotate the SNVs bioinformatics modelling was utilised to evaluate and predict the functional significance of mutations for each pedigree. A polymorphism phenotyping computational tool (PolyPhen-2) predicting potential impact of amino acid substitutions on the structure and function of the protein (8 sequence based and 3 structure based) was utilised [24]. The Polyphen-2 software was adjusted to more accurately predict the damaging effect of SNVs in the mouse genome [23]. PolyPhen score and predictive disruption indicated in Table 1.

Eosin-5-maleimide (ESM) staining of RBC cytoskeleton

E5M binds to band 3 and Rh-related proteins on RBCs and is utilised as a tool to assess changes in RBC surface area. ESM staining was based on a previously published assay [27]. Briefly, 0.5 mg/ml ESM was prepared in PBS. Ten microliters E5M (0.5 mg/ml) was mixed with 5µl of pre-washed murine RBC (PBS pH 7.4) and incubated (room temperature, dark, 1 hour) with intermittent mixing. RBCs were washed thrice with 500 µl PBS. On final wash the cell pellet was resuspended in 500 µl PBS. The labelled cell suspension was further diluted 1:10 in PBS for analysis via flow cytometry (BD FACSCanto II, 3 laser flow cytometer, BD Biosciences, USA).

Osmotic fragility

Differences in the osmotic fragility of murine RBC were evaluated by lysis in hypertonic saline, based on a previously published assay with some minor modifications [28]. Briefly, eleven hypertonic-saline solutions (0.9, 0.8, 0.75, 0.7, 0.65, 0.6, 0.55, 0.5, 0.45, 0.4, and 0.3% NaCl respectively) were prepared in milli-Q H2O. In a v-bottom 96 well microtitre plate, 2 µl of murine whole blood (representing approx. 2x10⁷ cells) was added followed by 200 µl of each saline solution or H2O (100% lysis control), and incubated (30 min, RT). After incubation, plates were centrifuged (1000xg, 5 min) and 100 µl of the supernatant was transferred to a fresh 96 well flat bottom microtitre plate. Haemolysis was measured at 450nm.

Quantification of IL-6 and RANTES via cytometric bead array (CBA)

Murine plasma was incubated with analyte-specific bead populations, and bound cytokine and chemokine analytes were detected with PE-conjugated antibody. Inflammatory mediators interleukin-6 (IL-6) and RANTES (CCL5), were quantified using Becton Dickenson (BD) CBA (BD Biosciences, Australia) according to the manufacturer’s instructions with minor modifications [29]. In brief, plasma was diluted 1:4 and incubated with 0.5µL of each capture bead for 1hr; 0.5µL of each detection reagent was then added and incubated for a further 2hr and analysed on a BD FACSComp II (BD Biosciences, Australia). FACSAarray software (BD Biosciences, CA, USA) was used for analysis to quantify concentrations from the standard curves run in parallel. Standard curves for IL-6 and RANTES assays ranged from 10-2500 pg/ml.
Quantification of erythropoietin and thrombopoietin via ELISA

Where indicated, levels of erythropoietin (EPO) and thrombopoietin (TPO) were assessed via ELISA according to manufactures instructions (MEP00B, MTP00; R&D systems, USA). Briefly, plasma was diluted 1:2 (TPO) or 1:5 (EPO) in respective assay diluents and incubated for 2hrs. Plates were washed and respective conjugate antibody added for 2hrs. Plates were washed before addition of substrate for 30min and reaction stopped with diluted hydrochloric acid. Absorbance measured at 450nm (540nm reference).

Statistical Analysis

Unpaired data was compared using a t-test. One-Way Analysis of Variance (ANOVA) was performed where indicated. GraphPad Prism (V) was used for all statistical analysis with 95% CI

Results

Identification of a novel ENU-pedigree with elevated reticulocyte count

For the forward genetic approach, 33 ENU-induced mutant pedigrees were screened for evidence of a changed blood picture. Screening resulted in identification of a subset of mice with an affected phenotype characterised by a significant elevation in reticulocyte count (p<0.0001 unpaired T-test affected cf. unaffected mice; Figure 1A). The affected mice were chosen for further breeding and analysis.

Identification of a novel mutation in RBC cytoskeleton protein ankryin-1

Exome sequencing of G4 affected mice identified a SNV in Ank1 (encoding RBC structural protein ankryin-1) as a candidate ENU-induced mutation resulting in the high reticulocyte phenotype. Sequencing revealed a G→A substitution on Chromosome 8 (base pair position 23,119,434; GRCm38); the first base of the splice donor site 5' of exon 34. The Ank1 mutation was predicted to result in a splice variant of ankryin-1 with a potential loss of the amino acids encoded for by exon 34 (Figure 1B). Ankryin-1 is an erythrocyte cytoskeletal protein that provides a link between RBC membrane structural proteins (spectrin and band 3) and the inner surface of the lipid bilayer [14,30]. The mutation reported here is different from previously reported Ank1 mutations in both humans [15,31] and mice [19,32-34]. Defects in ankryin-1 have been found in >50% of cases of HS in humans, characterised by evidence of haemolysis with anaemia, spherocytosis, reticulocytosis, jaundice, gallstones and splenomegaly [35]. This novel ankryin pedigree may model some forms of human HS and is a valuable tool for further characterisation of this disease. The pedigree was designated Ank1E34.

Investigation of haematological parameters in Ank1E34, band 4.1 and spectrin-β1 pedigrees

In a reverse genetics approach, four ENU pedigrees with SNV in genes encoding RBC structural proteins (band 4.1 and three individual spectrin-1β) were selected from the Australian Phenomics Facility missense mutation library [26]. Together with the novel Ank1E34 pedigree differential cell counts and standard haematological parameters were assessed (Table 3). In homozygous Ank1E34 mice, the significantly elevated reticulocyte count was consistently observed (p<0.0001), and was compounded with significantly decreased RBC count (p<0.0001), Hb (p<0.0001), HCT (p<0.0001), and MCV (p<0.0001). In addition, homozygous Ank1E34 mice exhibited thrombocytosis as evidenced by significantly elevated platelet count (p<0.0001: Table 3). Mice heterozygous for the Ank1 mutation also showed a significantly increased reticulocyte count (p=0.0026) and reduced MCV (p=0.0114; Table 3).

While mutation in Ank1 predominantly resulted in reduction of key RBC parameters indicating a disruption in RBC structural integrity, SNV in Spnb1 (a) and Spnb1 (b) resulted in elevated RBC parameters. In mice carrying homozygous Spnb1 (a) or Spnb1 (b) mutation, significantly increased RBC count (p=0.0211 (a), p=0.0476 (b)), haemoglobin (p=0.0253 (a), p=0.0432 (b)), and HCT (p=0.0186 (a), p=0.0431 (b)) was evident (Table 3). With the exception of a significantly increased MCV (p=0.0285) in heterozygous Spnb1 (b) mice, these altered blood parameters were not evident in the heterozygous Spnb1 (a) or (b) mice.
SNV in Spnb1 (c) or Epb4.1 did not significantly affect the haematological phenotype, as there was no significant difference between the blood picture in either homozygous or heterozygous mice with these mutations compared to their unaffected siblings (Table 3). Of note, the MCV and HCT was reduced in all mice studied from the b and 4.1 pedigree, regardless of the carriage of Epb4.1 mutation (unaffected, heterozygous or homozygous) and it is hypothesised that another causative mutation was responsible for the reduced red cell size in this pedigree.

**Increased osmotic fragility in Ank1<sup>EX34</sup> pedigree**

Standard osmotic fragility testing was performed on red cells from all pedigrees to investigate potential changes in RBC structural integrity. Homozygous Ank1<sup>EX34</sup> mice demonstrated significantly increased osmotic fragility (Figure 2A). There was no significant difference in the osmotic fragility of RBCs from mice with either homozygous or heterozygous for the Epb4.1 or any of the Spnb1 mutations (Figure 2B-E).

### Table 3. Differential cell counts and haematological parameters for ENU-mutant pedigrees [mean (SD)]. Whole blood from mice with homozygous (HOM) or heterozygous (HET) SNV in genes encoding RBC structural proteins were assessed for differences in haematological parameters using the ADVIA analyser. *p<0.05 unpaired T-test of unaffected siblings.

|                | Ankyrin-1 | Spectrin-1β (a) | Spectrin-1β (b) | Spectrin-1β (c) | Band 4.1 |
|----------------|-----------|-----------------|-----------------|-----------------|-----------|
|                | Hom n=5   | Het n=11 | Unaff* n=8 | Hom n=5 | Het n=7 | Unaff* n=5 | Hom n=5 | Het n=8 | Unaff* n=5 | Hom n=4 | Het n=3 | Unaff* n=2 | Hom n=2 | Het n=7 | Unaff* n=8 |
| **Differential Cell Count** |
| WBC            | 8.4       | 5.7       | 6.5  | 6.4  | 8.9  | 5.5  | 8.3  | 7       | 7       | 7       | 8.2  | 7      | 7      | 7.3    | 7.8    | 7.9    | 7.4    |
| (x10<sup>6</sup> cells/μL) (17.6) | (20.3) | (21.1) | (26.8) | (25.8) | (29.5) | (16.6) | (15.7) | (16.4) | (17.5) | (16.7) | (16.4) | (17.5) | (16.4) | (17.5) | (16.4) | (17.5) |
| RBC            | 7.2*      | 11.6     | 10.97| 12.1* | 11.4 | 10.3 | 12.2* | 10.9     | 10.9    | 11.6   | 9.9   | 10.7   | 10.4  | 10.3   | 10     |
| (x10<sup>6</sup> cells/μL) | (2.9) | (1.5) | (0.5) | (1.2) | (1.3) | (1.8) | (0.8) | (0.8) | (0.8) | (0.9) | (0.9) | (0.2) | (0.6) | (0.2) | (0.6) | (0.5) |
| Reticulocyte   | 1111.0*   | 428.1*   | 204.9| 236.8| 239.6| 248.0| 290.1| 298.3   | 349.5  | 261.7 | 294.2 | 278.8 | 265.1 | 255.7 | 292.5  |
| (x10<sup>6</sup> cells/μL) (60.4) | (92.0) | (55.9) | (26.4) | (69.3) | (226.8) | (54.5) | (65.4) | (115.2) | (51.0) | (30.6) | (33.7) | (51.9) | (35.6) | (62.7) |
| Platelet       | 2542*     | 1173     | 1278| 1298| 1375| 1164| 1258| 1129    | 1421   | 1311 | 1391 | 1290 | 1290 | 1201 | 1225 |
| (x10<sup>6</sup> cells/μL) | (61.8) | (211.9) | (232.3) | (267.1) | (263) | (148) | (183) | (151) | (147) | (243) | (24) | (93) | (214) | (150) |
| Hb (g/L)       | 127.2*    | 181.1   | 186.8| 210.6*| 199.6| 179| 200.4*| 189     | 182    | 201 | 184.7| 188 | 181 | 180.9 | 175.8 |
| (13.3) | (24.0) | (18.0) | (5.3) | (24.7) | (25.2) | (7.4) | (21.0) | (14.7) | (15.1) | (12.7) | (2.8) | (7.1) | (11.6) | (16.7) |
| HCT            | 0.30*     | 0.47     | 0.55| 0.52 | 0.47 | 0.60* | 0.5 | 0.5      | 0.5     | 0.6   | 0.5  | 0.51 | 0.43 | 0.42 | 0.42 |
| (0.06) | (0.06) | (0.05) | (0.07) | (0.05) | (0.04) | (0.05) | (0.05) | (0.05) | (0.01) | (0.01) | (0.02) |
| MCV (fL)       | 81.6      | 40.7*   | 45.6| 45.3 | 45.6 | 46.6 | 46.4 | 48.3*   | 45.9    | 47.7 | 48.8 | 47.3 | 41.4 | 41.4 | 41.8 |
| (1.7) | (3.9) | (2.5) | (1.8) | (2.1) | (1.3) | (1.7) | (1.5) | (1.6) | (2.2) | (0.1) | (0.4) | (0.3) | (0.8) |

*Unaff refers to unaffected siblings in the pedigree.

![Figure 2. Osmotic fragility of RBC from ENU pedigrees. A) RBC from the ANK-1<sup>EX34</sup> pedigree (ankyrin-1) had increased osmotic fragility (ANOVA p<0.0001). Homozygous ANK-1<sup>EX34</sup> had increased osmotic fragility compared to both the background and heterozygous mice (p<0.001, p<0.05 respectively; Tukey post-test). B-E) No difference in RBC osmotic fragility for band 4.1 or any of the spectrin-1β pedigrees.](image-url)
Damaged or atypical RBCs are sequestered in the spleen and removed from circulation. Splenomegaly is a common feature in humans with HS and splenectomy is sometimes required \[35\].

Ank1\(^{EX34}\) mice were sacrificed and spleens excised to investigate abnormal RBC clearance. As expected, spleens from homozygous Ank1\(^{EX34}\) mice were enlarged, consistent with sequestration of abnormal RBC and/or increased RBC turnover (Figure 5). Increased RBC turnover and associated splenomegaly may lead to an inflammatory response. IL-6 and CCL5 (RANTES) were quantified in plasma of Ank1\(^{EX34}\) mice as an indication of inflammation. IL-6 was not detected in any of the samples assayed and there was no change in levels of CCL5 attributed to Ank1\(^{EX34}\) mutation (data not shown). EPO and TPO are key growth factors involved in RBC and platelet differentiation and haemostasis. EPO is a glycoprotein hormone that signals to increase RBC turnover and expression is increased in hypoxic conditions \[39\]. EPO levels were significantly increased in homozygous Ank1\(^{EX34}\) mice compared to heterozygotes and unaffected siblings (p=0.021, p=0.001 respectively, Figure 6A). Heterozygous Ank1\(^{EX34}\) mice also had significantly elevated EPO levels compared to unaffected siblings (p=0.004, Figure 6A). TPO is a humoral growth factor that is necessary for megakaryocyte proliferation and maturation, as well as for thrombopoiesis \[40\]. Homozygous Ank1\(^{EX34}\) mice had significantly reduced TPO levels compared to unaffected siblings (p=0.04, Figure 6B). The reduction in circulating TPO in homozygous Ank1\(^{EX34}\) mice is likely due to depletion via c-Mpl receptor binding consistent with the elevated platelet count in this pedigree.

**Discussion**

Murine RBCs provide a suitable platform to study genetically defined changes in RBCs that may impact on structural integrity, differentiation and lifespan. These features are central to RBC
functionality and any changes or disruption in RBC parameters may impact on the storage capacity of the blood component, and further may result in poor patient outcomes post-transfusion. Post-collection packed red blood cells are stored for up to 42 days before transfusion. Clinical studies have reported an association between RBC storage and increased patient morbidity post-transfusion [3-5], and there is evidence of donor variability in the lifespan of RBC in storage and onset of the storage lesion [6]. In this study, we used murine ENU models with both forward and reverse genetic approaches to study genetic-based changes in RBC parameters that may have important implications for storage of blood components for clinical use and transfusion outcomes in humans.

For the reverse genetics approach ENU pedigrees were chosen for investigation based on mutation in RBC structural proteins. At the commencement of the study, there were four defined mutations in genes encoding RBC structural proteins available for study; one mutation in Epb4.1 [encoding band 4.1] and three separate mutations in Spnb1 [encoding spectrin-1β]. Band 4.1 and spectrin-1β are functionally important RBC cytoskeleton proteins. Band 4.1 associates with a number of RBC structural proteins including spectrin, actin, adducin, dematin, tropomodulin, tropomyosin, band 3 and glycophorin C in the 4.1R complex which spans the lipid bilayer [41]. Spectrin-1β is an intracellular self-assembling protein that in association with spectrin-1α forms an anchoring point for the band 3 and band 4.1R complexes. Thus both band 4.1 and spectrin-1β are key structural proteins that contribute to the stability and elasticity of the RBC. Mutations in these proteins have the potential to affect RBC structural integrity, differentiation and survival.

All of the SNVs studied in the spectrin-1β pedigrees occurred in the region encoding the spectrin-binding domain of the protein. It is not surprising that ENU mutagenesis would result in a number of mutations in this region as a large portion of Spnb1 encodes the spectrin-binding domain. Of the three Spnb1 SNVs studied, Spnb1(c) had the highest prediction of loss of function based on bioinformatic modelling. However, this mutation had the least impact of the three Spnb1 mutations studied, with the pedigree exhibiting no evidence of altered haematological profile, and no difference in RBC structural integrity in terms of osmotic fragility or ESM binding. The spectrin-1β (a) and (b) pedigrees were both characterised by significantly increased RBC count, Hb and HCT, despite the low PolyPhen score and prediction of a benign mutation. Although there were increases in the RBC count (and associated Hb and MCV) in the spectrin-1β (a) and (b) pedigrees, the RBC did not appear to have altered structural integrity as no changes were apparent in osmotic fragility or ESM binding.

The SNV in Epb4.1 results in a Thr→Ala amino acid substitution in the hydrophilic domain of the encoded band 4.1 protein and bioinformatic modelling determined this mutation was “probably damaging”. Despite the PolyPhen score and predicted disruption, we saw no evidence of changed blood picture due to mutation in Epb4.1. We observed a consistently reduced MCV and HCT in this pedigree, regardless of the presence or absence of the defined mutation in Epb4.1. ENU mutagenesis results in multiple mutations in the murine germ line and the reduced MCV and HCT is likely the result of a dominant mutation in another gene. Retrospectively, we assessed the other mutations reported to be present in the band 4.1 pedigree. There were 46 other SNV identified and the majority of the mutations were in genes primarily associated with cancer, cell cycle/survival and development and cardiovascular disease.

Of the 46 additional SNVs in the band 4.1 pedigree, on the basis of currently described function, mutations in Trank1, E2f8, Etnk2 and Yars2 will be the first investigated to determine if these mutations are associated with the reduced MCV and HCT in this pedigree. Trank1 encodes tetratricopeptide repeat and ankyrin repeat-containing protein 1, a protein predicted to contain multiple ankyrin repeat domains. To date, there are limited reports on the function of
this gene product, however, the presence of numerous ankyrin repeats and predicted “probably damaging” PolyPhen score as a result of a Phe→Leu amino acid substitution suggests SNV in Trank1 has the potential to impact on RBC structural integrity. E2B8 encodes E2f transcription factor 8. This transcription factor is also not well described however putative roles in cell cycle, endocycle and placental development have been reported [42]. Dysfunction in E2B8 has been linked to anaemia [43]. The mutation in E2B8 is predicted to be “possibly damaging” as a result of Ser→Ile amino acid substitution. Mutations in Etnk2 and Yars2 were also predicted to be “possibly damaging”. Etnk2 encodes ethanolamine kinase 2, a member of the choline/ethanolamine kinase family. This enzyme catalyses the first step of phosphatidylethanolamine biosynthesis and deficiency has been associated with altered haematologic parameters in mice [44]. Yars2 encodes tyrosyl-tRNA synthetase 2a, a mitochondrial protein that catalyses the attachment of tyrosine to tRNA. Mutations in this gene are associated with myopathy, lactic acidosis and sideroblastic anaemia type 2 [45].

Based on the presentation of the phenotype in all band 4.1 mice regardless of Epb4.1 SNV carriage, we hypothesise an autosomal-dominant inheritance and matings for this pedigree are being designed to assist in the analysis of the causative mutation.

Using the forward genetic approach a novel ENU-mutant pedigree with an elevated reticulocyte count was identified. Further analysis revealed reduced Hb and lower MCV. Sequencing revealed a G→A substitution on Chromosome 8 (base pair position 23,119,434; GRCh38); the first base of the splice donor site 5′ of Ank1 exon 34. The Ank1 SNV occurs in a splice site motif in ankyrin-1 likely to be associated with loss of the exon 34 amino acid sequence. Ankyrin-1 is an erythrocyte cytoskeletal protein that provides a link between RBC membrane structural proteins (spectrin and band 3) and the inner surface of the lipid bilayer [14,30]. Mutations in Ank1 have been associated with hereditary spherocytosis (HS), an inherited haemolytic anaemia characterised by rigid spheroid RBCs [35]. Patients with spherocytosis exhibit anaemia with a compensatory reticulocytosis as a result of haemolysis of spherocytic red cells, jaundice, gallstones and splenomegaly [35].

The Ank1 SNV reported in this study was different to previously reported Ank1 mutations in both humans [15,31] and mice [19,32-34], although the phenotypes were similar. The Ank1E344 pedigree characterised in this study demonstrates elevated reticulocyte count, reduced Hb, lower MCV, splenomegaly, reduced RBC ESM staining and increased RBC fragility, all of which are characteristic of HS. The Ank1E344 pedigree also exhibited thrombocytosis, a characteristic not commonly associated with Ank1 mutation or HS. Ank1 mutations have also been associated with increased malarial resistance in a number of murine studies [34], and human HS as a result of Ank1 mutation may be the result of evolution to prevent malarial infection. While malarial resistance was not the focus of our study, it is a reasonable hypothesis that the Ank1E344 pedigree would demonstrate a resistance to malarial infection.

To further characterise this novel Ank1E344 pedigree, we also studied potential changes in inflammation and modulation of RBC and platelet growth factors. Despite an altered haematological phenotype and splenomegaly in the Ank1E344 pedigree, we did not find evidence of changes in the inflammatory mediators we studied. IL-6 is a pro-inflammatory cytokine, primarily synthesised by the liver. IL-6 is a pleiotropic cytokine with key roles in infection, inflammation, autoimmunity and tissue haemostasis [46]. IL-6 levels were at the limit of detection (<10pg/ml) in the Ank1E344 pedigree, despite the clear dysfunction in a number of key biological systems in these mice. We also studied EPO and TPO as two key cytokines that contribute to RBC and platelet differentiation and haemostasis. EPO was significantly increased in both heterozygous and homozygous Ank1E344 mice. EPO synthesis is increased in response to hypoxia and signals erythroid progenitor cells to differentiate into erythroblasts [39]. As the Ank1E344 pedigree was not the first instance by an elevated reticulocyte count, it was not surprising that a significantly elevated EPO was associated with this phenotype. TPO is a humoral growth factor that is necessary for megakaryocyte proliferation and maturation, as well as for thrombopoiesis [40]. We observed significantly reduced TPO in homozygous Ank1E344 mice. As these mice also exhibit thrombocytosis, it is likely the reduction in circulating TPO is due to depletion via c-Mpl receptor binding on platelets, though other mechanisms may also contribute to the TPO feedback loop, as high platelet count does not always correlate with reduced levels of TPO in the circulation [47,48].

Using murine genetic models derived by ENU mutagenesis, RBC structural proteins were characterised in five pedigrees. Using a forward genetic screening approach we identified a phenotype characterised by reticulocytosis, microcytic anaemia and thrombocytosis. This phenotype was determined to be associated with a novel mutation in Ank1, encoding the RBC structural protein ankyrin-1. The forward approach was therefore a useful tool to identify and characterise the genetic basis of an altered haematological phenotype. As the Ank1E344 mutation is in a splice motif, there is no PolyPhen score associated with this SNV. Four pedigrees were investigated from a reverse genetics approach, to identify a phenotype associated with the presence of a known mutation. For the SNVs studied we found the PolyPhen score was not correlated with a changed phenotype for any of the assays employed. There was no evidence of altered haematological parameters or RBC structural integrity resulting from the two SNVs that were predicted to result in a damaging phenotype (Spnb1c) and Epb4.1. These mutations may be damaging, however altered phenotype may not have been evident due to molecular redundancy. The two SNVs predicted to be benign (Spnb1 (a) and (b)) demonstrated an increased RBC count, HCT and Hb. Our findings suggest that new generations of bioinformatic prediction tools used in concert with feedback from phenotypic analysis will improve capacity to predict altered function.

This study was established in the context of understanding factors that may influence the outcomes of blood transfusion. The haemoglobin increment following transfusion is highly variable and there are minimal studies of non-serological variables associated with differences in post-transfusion survival of RBC. In this study we targeted SNVs in genes encoding proteins critical for RBC function that are expected to be important in post-transfusion RBC survival. The Ank1 mutation is clearly associated with anaemia and elevated RBC turnover. The impact of the Spnb1 mutations, while resulting in statistically significant increases in Hb does not produce profound changes that could be viewed as a disease, however they may be associated with altered post-transfusion RBC lifespan. These murine models provide a tool to study the contribution of genetic change to donor variability in blood component storage and post-transfusion RBC survival that may be associated with transfusion outcomes.

Acknowledgements
We would like to thank Belinda Whittle for her contributions including expert review of the manuscript. We acknowledge the Australian Governments that fully fund the Australian Red Cross Blood Service for the provision of blood products and services to the Australian community. The Australian Phenomics Facility missense mutation project is funded by the Australian Government as part of the Super Science Initiative and financed from the Education Investment Fund.
ENU-induced Mutations in RBC Structural Proteins

References

1. Hovav T, Yedgar S, Manny N, Barshtein G (1999) Alteration of red cell aggregability and shape during blood storage. Transfusion 39: 277-281.
2. Bennet-Guerrero E, Veldman TH, Doctor A, Telen MJ, Orel TL, et al. (2007) Evolution of adverse changes in stored RBCs. Proceedings of the National Academy of Sciences 104: 17063-17068.
3. Koch CG, Li L, Sessler DI, Figueira P, Hoeltge GA, et al. (2008) Duration of red-cell storage and complications after cardiac surgery. New England Journal of Medicine 358: 1229-1239.
4. Leal-Noval SR, Jara-López I, García-Garmendia JL, Martín-Niebla A, Herruzo-Avilés A, et al. (2003) Influence of erythrocyte concentrate storage time on posttransfusion morbidity in cardiac surgery patients. Anesthesiology 98: 815.
5. Zallen G, Offner PJ, Moore EE, Blackwell J, Ciesla DJ, et al. (1999) Age of transfused blood is an independent risk factor for postinjury multiple organ failure. American journal of surgery 178: 570.
6. Hess J (2006) An update on solutions for red cell storage. Vox Sanguinis 91: 13-19.
7. Sarantseva SV, Schwarzman AL (2009) Modern genetic approaches to searching for targets for medicinal preparations. Russian Journal of Genetics 45: 761-770.
8. García-García MJ, Eggenschwiler JT, Caspary T, Alcorn HL, Wyler MR, et al. (2005) Analysis of mouse embryonic patterning and morphogenesis by forward genetics. Proceedings of the National Academy of Sciences 102: 5913-5919.
9. Nelms KA, Goodnow CC (2001) Genome-wide ENU mutagenesis to reveal immune regulators. Immunity 15: 409-418.
10. Westrick RJ, Winn ME, Eizman DT (2007) Murine models of vascular thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology 27: 2079-2093.
11. Cohen CM, Branton D (1981) The normal and abnormal red cell cytoskeleton: a renewed search for molecular defects. Trends in Biochemical Sciences 6: 266-268.
12. Manno S, Takakuwa Y, Mohandas N (2002) Identification of a functional role for lipid asymmetry in biological membranes: Phosphatidylserine-skeletal protein interactions modulate membrane stability. Proceedings of the National Academy of Sciences 99: 1943-1948.
13. An X, Zhang X, Debnath G, Baines AJ, Mohandas N (2006) Phosphatidylinositol-4, 5-biphosphate (PIP2) differentially regulates the interaction of human erythrocyte protein 4.1 (4.1 R) with membrane proteins. Biochemistry 45: 5725-5732.
14. Bennett V, Stenbuck PJ (1979) Identification and partial purification of ankyrin, the high affinity membrane attachment site for human erythrocyte spectrin. Journal of Biological Chemistry 254: 2533-2541.
15. Nakashima H, Kanazaki A, Yawata A, Yamada O, Yawata Y (2001) Ankyrin gene mutations in Japanese patients with hereditary spherocytosis. International journal of hematology 73: 54-63.
16. Nakashima K, Beutler E (1979) Erythrocyte cellular and membrane deformability in hereditary spherocytosis. Blood 53: 481-485.
17. Southgate CD, Chishiti AH, Mitchell B, Yi SJ, Palek J (1996) Targeted disruption of the murine erythroid band 3 gene results in spherocytosis and severe haemolytic anaemia despite a normal membrane skeleton. Nature Genetics 14: 227-230.
18. Reliene R, Mariani M, Zanella A, Reinhart WH, Ribeiro ML, et al. (2002) Splenectomy prolongs in vivo survival of erythrocytes differently in spectrin/ankyrin- and band 3-deficient hereditary spherocytosis. Blood 100: 2208-2215.
19. Rank G, Sutton R, Marshall V, Lundie RJ, Caddy J, et al. (2009) Novel roles for erythroid Ankyrin-1 revealed through an ENU-induced null mouse mutant. Blood 113: 3352-3362.
20. Pasini EM, Kirkegaard M, Salerno D, Mortensen P, Mann M, et al. (2008) Deep Coverage Mouse Red Blood Cell Proteome A First Comparison with the Human Red Blood Cell. Molecular & Cellular Proteomics 7: 1317-1330.
21. Goodman JW, Smith L (1961) Erythrocyte life span in normal mice and in radiation bone marrow chimeras. American Journal of Physiology–Legacy Content 200: 764-770.
22. Ryan T, Ciavatta D, Townes T (1997) Knockout-transgenic mouse model of sickle cell disease. Science 278: 873-876.
23. Kean LS, Brown LE, Nichols JW, Mohandas N, Archer DR, et al. (2002) Comparison of mechanisms of anemia in mice with sickle cell disease and β-thalassemia: peripheral destruction, ineffective erythropoiesis, and phospholipid scramblase-mediated phosphatidylinerine exposure. Experimental hematology 30: 394-402.
24. Merkle S, Prestch W (1993) Glucose-6-phosphate isomerase deficiency associated with nonpheripheral hemolytic anemia in the mouse: an animal model for the human disease. Blood 81: 206-213.
25. Andrews T, Whittle B, Field M, Balakishnan B, Zhang Y, et al. (2012) Massively parallel sequencing of the mouse exome to accurately identify rare, induced mutations: an immediate source for thousands of new mouse models. Open biology 2: 120061.
26. Australian Hemovigilance Facility (2013) Missense Mutation Library. http://databases.apf.edu.au/mutations/.
27. King MJ, Behrens J, Rogers C, Flynn C, Greenwood D, et al. (2000) Rapid flow cytometric test for the diagnosis of membrane cytoskeleton-associated haemolytic anaemia. British Journal of Haematology 111: 924-933.
28. Veale MF, Healey G, Sparrow RW (2011) Effect of additive solutions on red blood cell (RBC) membrane properties of stored RBCs prepared from whole blood held for 24 hours at room temperature. Transfusion 51: 255-33S.
29. Tarnok A, Hambsch J, Chen R, Varro R (2003) Cytometric Bead Array to Measure Six Cytokines in Twenty-Five Microliters of Serum. Clin Chem 49: 1000-1002.
30. Bennett V, Stenbuck PJ (1979) The membrane attachment protein for spectrin is associated with band 3 in human erythrocyte membranes.
31. Eber SW, Gonzalez JM, Lux ML, Scarpa AL, Tse WT, et al. (1996) Ankyrin-1 mutations are a major cause of dominant and recessive hereditary spherocytosis. Nature Genetics 13: 214-218.
32. Birkenmeier CS, Gifford EJ, Barker JE (2003) Normoblastosis, a murine model for ankyrin-deficient hemolytic anemia, is caused by a hypomorphic mutation in the erythroid ankyrin gene Ank1. The Hematological Journal 4: 445-449.
33. Hughes MR, Anderson N, Maltby S, Wong J, Berberovic Z, et al. (2011) A novel ENU-generated truncation mutation lacking the spectrin-binding and C-terminal regulatory domains of Ank1 models severe hemolytic hereditary spherocytosis. Experimental hematology 39: 305-320. e302.
ENU-induced Mutations in RBC Structural Proteins

34. Greth A, Lampkin S, Mayura-Guru P, Rodda F, Drysdale K, et al. (2012) A novel ENU-mutation in ankyrin-1 disrupts malaria parasite maturation in red blood cells of mice. PLoS One 7: e38999.
35. An X, Mohandas N (2008) Disorders of red cell membrane. British journal of haematology 141: 367-375.
36. Kedar P, Colah R, Kulkarni S, Ghosh K, Mohanty D (2003) Experience with eosin-5′-maleimide as a diagnostic tool for red cell membrane cytoskeleton disorders. Clinical & Laboratory Haematology 25: 373-376.
37. King MJ, Smythe JS, Mushens R (2004) Eosin-5′-maleimide binding to band 3 and Rb-related proteins forms the basis of a screening test for hereditary spherocytosis. British journal of haematology 124: 106-113.
38. Girottoni F, Garcon L, Bergoin E, Largier M, Deaunay J, et al. (2008) Usefulness of the eosin-5′-maleimide cytometric method as a first-line screening test for the diagnosis of hereditary spherocytosis: comparison with ectactometry and protein electrophoresis. British journal of haematology 140: 468-470.
39. Chateaurieux S, Grigorakaki C, Morceau F, Dicato M, Diederich M (2011) Erythropoietin, erythropoiesis and beyond. Biochemical Pharmacology 82: 1291-1303.
40. de Graaf CA, Metcalf D (2011) Thrombopoietin and hematopoietic stem cells. Cell Cycle 10: 1582-1589.
41. Salomao M, Zhang X, Yang Y, Lee S, Hartwig JH, et al. (2008) Protein 4.1R-dependent multiprotein complex: New insights into the structural organization of the red blood cell membrane. Proceedings of the National Academy of Sciences 105: 8026-8031.
42. Li J, Ran C, Li E, Gordon F, Comstock G, et al. (2008) Synergistic function of E2F7 and E2F8 is essential for cell survival and embryonic development. Developmental cell 14: 62-75.
43. Hu T, Ghazaryan S, Sy C, Wiedmeyer C, Chang V, et al. (2012) Concomitant inactivation of Rb and E2F8 in hematopoietic stem cells synergizes to induce severe anemia. Blood 119: 4532-4542.
44. Tian Y, Jackson P, Gunter C, Wang J, Rock CO, et al. (2006) Placental thrombosis and spontaneous fetal death in mice deficient in ethanolamine kinase 2. Journal of Biological Chemistry 281: 28438-28449.
45. Sasarman F, Nishimura T, Thiffault I, Shoubridge EA (2012) A novel mutation in YARS2 causes myopathy with lactic acidosis and sideroblastic anemia. Human Mutation 33: 1201-1206.
46. Kishimoto T (2010) IL-6: from its discovery to clinical applications. International Immunology 22: 347-352.
47. Uppenkamp M, Makarova E, Petrasch S, Brittinger G (1998) Thrombopoietin serum concentration in patients with reactive and myeloproliferative thrombocytosis. Annals of hematology 77: 217-223.
48. Cerutti A, Custodi P, Duranti M, Noris P, Balduini CL (1997) Thrombopoietin levels in patients with primary and reactive thrombocytosis. British journal of haematology 99: 281-284.

Keywords:
Red Blood Cell, N-ethyl-N-nitrosourea (ENU), Ankyrin, Spectrin-1β, Band 4.1, Missense Library

Competing Interests:
The authors have declared that no competing interests exist.

© 2013 Kildey et al. Licensee: Computational and Structural Biotechnology Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly cited.

What is the advantage to you of publishing in Computational and Structural Biotechnology Journal (CSBJ) ?
- Easy 5 step online submission system & online manuscript tracking
- Fastest turnaround time with thorough peer review
- Inclusion in scholarly databases
- Low Article Processing Charges
- Author Copyright
- Open access, available to anyone in the world to download for free

WWW.CSBJ.ORG